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Abstract 
The inositol 1,4,5-trisphosphate (IP3) receptor (IP3R) type 2 (IP3R2) is an intracellular 
Ca2+-release channel located on the endoplasmic reticulum (ER). It displays in many 
cell types a predominantly perinuclear or even nuclear localization. IP3R2 is 
characterized by a high sensitivity to both IP3 and ATP and is biphasically regulated by 
Ca2+. Interestingly, ATP stimulates IP3R2 independently of the cytosolic [Ca
2+]. 
Furthermore, IP3R2 is modulated by phosphorylation events mediated by e.g. protein 
kinase A, Ca2+/calmodulin-dependent kinase II and protein kinase C. In addition to its 
regulation by protein kinase A, IP3R2 forms a complex with adenylate cyclase 6 and is 
directly regulated by cAMP, thereby linking in a new way Ca2+-dependent and cAMP-
dependent signalling. Finally, in the ER, IP3R2 is less mobile than the other IP3R 
isoforms, while its functional properties appear dominant in heterotetramers. These 
properties make the IP3R2 a Ca
2+ channel with exquisite properties for setting up 
intracellular Ca2+ signals with unique characteristics. IP3R2 plays a crucial role in the 
function of secretory cell types (e.g. pancreatic acinar cells, hepatocytes, salivary gland, 
eccrine sweat gland). In cardiac myocytes, the role of IP3R2 appears more complex, 
because, together with IP3R1, it is needed for normal cardiogenesis, while its aberrant 
activity is implicated in cardiac hypertrophy and arrhythmias. Moreover, IP3R2 
expression is driven by IP3-induced Ca
2+ release leading to a self-perpetuating system 
of cardiac hypertrophy. Most importantly, its high sensitivity to IP3 makes IP3R2 a target 
for anti-apoptotic proteins (e.g. Bcl-2) in B-cell cancers. Disrupting IP3R/Bcl-2 interaction 
therefore leads in those cells to increased Ca2+ release and apoptosis. Intriguingly, 
IP3R2 is not only implicated in apoptosis but also in the induction of senescence, 
another tumour-suppressive mechanism. These results were the first to unravel the 
physiological and pathophysiological role of IP3R2 and we anticipate that further 
progress will soon be made in understanding the function of IP3R2 in various tissues 
and organs. 
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Abbreviations: 
AC6   Adenylate cyclase type 6 
AKT/PKB  Protein kinase B 
ANF   Atrial natriuretic factor 
Bcl   B-cell lymphoma 
BH   Bcl-2 homology domain 
CaMKII  Ca2+/calmodulin dependent protein kinase II 
DT40 TKO  DT40 triple knockout 
EMT   Epithelial-mesenchymal transition 
ER   Endoplasmic reticulum 
ETAR   Endothelin receptor type A 
HDAC   Histone deacetylase 
HEC   Immortalized human mammary epithelial cells 
IP3   Inositol 1,4,5-trisphosphate 
IP3R(1, 2, 3)  Inositol 1,4,5-trisphosphate receptor (type 1, type 2, type 3) 
NFAT   Nuclear factor of activated T cells 
PKA   Protein kinase A 
PKC   Protein kinase C 
Po   Open probability 
ROS   Reactive oxygen species 
RyR   Ryanodine receptor 
SERCA  Sarco/endoplasmic reticulum Ca2+ ATPase 
SRF   Serum response factor 
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1. Introduction 
The inositol 1,4,5-trisphosphate (IP3) receptors (IP3Rs) are ubiquitously expressed 
intracellular Ca2+-release channels. These channels are tetrameric in structure and 
predominantly localized in the endoplasmic reticulum (ER). IP3, produced by 
phospholipase C after cell activation by hormones, growth factors or neurotransmitters, 
diffuses into the cytosol, binds to and activates the IP3R, leading to Ca
2+ release from 
the ER. This Ca2+ release is instrumental in the formation of the spatio-temporal Ca2+ 
signals, fundamental for the regulation of multiple cellular processes, including 
proliferation, differentiation, metabolism, secretion, cell fate and memory [1-3]. 
In all vertebrate organisms, three different genes encode IP3Rs, leading to three main 
types of IP3Rs, IP3R1 (first fully cloned in 1989 [4]), IP3R2 (first fully cloned in 1991 [5]) 
and IP3R3 (first fully cloned in 1993 [6]). Each monomer is about 2700 amino acids in 
length and consequently has a predicted molecular mass of approximately 300 kDa. 
The IP3R proteins are structurally and functionally divided into 5 distinct domains: the N-
terminal coupling domain (a.k.a. suppressor domain), the IP3-binding core, the internal 
coupling domain (a.k.a the modulatory and transducing domain), the channel domain 
and the C-terminal coupling domain (a.k.a. the gatekeeper domain) [7]. The three IP3R 
isoforms share only 60-80 % overall similarity at the amino acid level, but the similarity 
is much higher in certain defined regions (e.g. the IP3-binding site, the 5
th and 6th 
transmembrane regions, putative ER-retention signals) while much lower in others, 
allowing for the existence of very distinct properties between the isoforms (see section 
2). Finally, a further diversity can result from alternative splicing and the formation of 
heterotetramers [1, 8, 9]. 
The vast majority of cell types express more than one IP3R isoform but their relative 
proportion can be highly variable [10-14]. Moreover, in various cases it was shown that 
the relative expression levels depended on the differentiation or developmental state of 
the cells or could be modulated by specific treatments (e.g. [14-21]). 
The participation of the IP3Rs in establishing distinct patterns of Ca
2+ signals resulting in 
different cellular outcomes depends therefore on the complement of the various IP3R 
(splice) isoforms expressed, their intracellular location, the presence of regulatory 
factors, including associated proteins, and their phosphorylation status [1, 14, 22-25]. 
On the basis of their almost exclusive expression of a single IP3R isoform, some cell 
types have been used as model system for the analysis of the role of the different IP3R 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
6 
 
isoforms [8]. However, only a rather limited set of cell types expresses predominantly 
IP3R2 (Table 1).  
Interestingly, in many cells IP3R2 is expressed at a different subcellular location than 
the other IP3R isoforms. For example, in bovine aortic endothelial cells, bovine adrenal 
glomerulosa cells and COS-7 cells [26], the HepG2 liver cell line [27] and the 
hippocampal cell line HT22 [28] IP3R2 displayed a predominantly nuclear localization, 
while in hepatocytes IP3R2 is confined to the apical pole of the cell, near the canalicular 
membrane [29].  
The nuclear localization of IP3R2 is particularly interesting with respect to the role of 
Ca2+ signalling in the nucleus, e.g. for gene transcription. Although the presence of 
IP3Rs in the inner leaflet of the nuclear envelope remains the subject of debate [30-32], 
there is at least strong evidence that a subset of the IP3R2 is facing the nucleoplasm in 
HepG2 cells [27], in SKHep1 cells [33] and in atrial myocytes [34] where they can 
control Ca2+ release directly into the nucleus. 
Information concerning the regulation of IP3R2 expression is likewise still quite limited. 
The 5’-flanking region of murine IP3R2 has been sequenced and contained at least 7 
transcription initiation sites with an upstream promoter containing no conventional TATA 
box but a GC box [35]. To the best of our knowledge, only two recent studies described 
pathways involved in the regulation of IP3R2 expression. First, in the heart, direct 
binding of nuclear factor of activated T cells (NFAT) c1 to the IP3R2 promoter drives 
IP3R2 expression [36]. Second, in dendritic cells, IP3R2 expression is controlled by the 
transcription factor ETS1, which itself depends on protein kinase B (AKT/PKB) 2 [37]. 
Finally, although not yet understood at the mechanistic level, in the HT22 cell line, 
oxidative stress leads to a specific upregulation of IP3R2 [38] (see section 5). 
Splicing of IP3R2 is much less documented than that of IP3R1, but two different splice 
variants have been described. One appears to be muscle-specific and is limited to the 
N-terminal 175 amino acids of IP3R2 supplemented with 6 additional amino acids; 
although a regulatory role has been proposed, its function has not yet been elucidated. 
[39]. The second splice variant uses the same splice acceptor site and is lacking amino 
acids 176-208. The deletion is localized fully within the suppressor domain, which plays 
an important role in both the regulation of IP3 binding and in the coupling of the IP3R N-
terminus to the channel region [40]. As a consequence, the resulting protein is defective 
in both IP3 binding and Ca
2+ release. However, its expression in cells prevents the 
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agonist-dependent clustering of the endogenous IP3Rs, probably via 
heterotetramerization, and can therefore impact intracellular Ca2+ signalling [41].  
Finally, also at the protein level, IP3R2 levels appear to be regulated in a different 
manner when compared to the other isoforms. While all IP3R isoforms are 
downregulated under conditions of chronic stimulation [12, 42, 43], IP3R2 appeared the 
least susceptible [12]. 
In spite of the unique molecular properties displayed by IP3R2 (see sections 2.1-2.5), 
this protein is much less investigated than IP3R1 or indeed, even IP3R3. This apparent 
lack of progress was probably in retrospect multifaceted. The low general abundance of 
IP3R2 and the lack of good model systems for its investigation partially explain the fewer 
studies directed specifically towards the IP3R2. Additionally, but no less importantly, it 
appeared that it was historically difficult to make IP3R2 expression constructs. 
Moreover, the quality of the antibodies raised against IP3R2 was also generally poor. 
Finally, a recent analysis of classically used IP3R inhibitors demonstrated that IP3R2 
expressed in DT40 triple knockout (DT40 TKO) chicken B lymphocytes was the least 
sensitive of all the IP3R isoforms to heparin, caffeine and 2-aminoethoxydiphenyl borate 
[44]. This latter observation may explain why pharmacological approaches to discern 
IP3R2 function have been largely unsuccessful. 
Notwithstanding these issues, recent work has begun to unravel the significance of 
IP3R2 in a number of physiological settings. The aim of this review is therefore to 
highlight these important functions of IP3R2 and to so stimulate further research in the 
field. 
 
2. Specific molecular and cellular properties of IP3R2 
IP3R2 has a high sequence and structural homology with the other IP3R isoforms and 
consequently shares a large number of properties with IP3R1 and IP3R3. In this chapter, 
we will therefore focus on specific properties in which the IP3R2 clearly differs from the 
other isoforms (Figure 1). 
2.1 IP3 affinity 
Binding of IP3 to the IP3-binding core is the key step needed for the induction of IP3-
induced Ca2+ release. As stated above (see section 1), the three IP3R isoforms all have 
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a very similar structure [45]. For example, all IP3R isoforms contain their IP3-binding 
core towards their N-terminus, preceded by the so-called suppressor domain [46].  
A striking property of the IP3R2 is its much higher affinity for IP3 when compared with 
the two other IP3R isoforms. This was first observed in IP3-binding experiments, which 
under various conditions demonstrated a rank-order of IP3 affinities IP3R2 > IP3R1 > 
IP3R3 [5, 10, 47]. Subsequent studies conclusively demonstrated that the IP3-binding 
cores of each of the IP3R isoforms display a similar affinity for IP3 (about 2 nM), but as 
demonstrated by the analysis of normal and chimeric N-terminal domains of the 
different IP3R isoforms the presence of the suppressor domain determines the specific 
IP3 affinity of the isoform (50, 14 and 163 nM for IP3R1, IP3R2 and IP3R3, respectively). 
These results underpin the importance of the suppressor domain for IP3R function [46].  
The difference in IP3 affinity is also reflected in functional experiments. Analysis of IP3-
induced Ca2+ release in DT40 TKO cells expressing a single IP3R isoform demonstrated 
that DT40 TKO cells heterologously expressing a single IP3R isoform could sustain Ca
2+ 
oscillations for an extended period after stimulation by an anti B-cell receptor antibody 
only if the expressed isoform was IP3R2 [48]. Very similar results were obtained in 
vascular myocytes, whereby only the cells expressing IP3R2 in addition to IP3R1 
displayed a Ca2+ oscillation pattern [49, 50]. Comparison of native IP3R1 (from 
cerebellum) and IP3R2 (from heart) [51] or the comparative analysis of each of the three 
IP3R isoforms heterologously expressed in Sf9 insect cells [52] also confirmed the rank-
order of the sensitivity of channel opening towards IP3 as IP3R2 > IP3R1 > IP3R3, when 
measured after incorporation in planar lipid bilayers. 
It must however be pointed out that a number of studies found a rank-order of affinities 
that is different from that mentioned above [53, 54]. Although this discrepancy has never 
been fully clarified, it can be assumed that variability in the experimental conditions (e.g. 
pH, [Ca2+]) as well as in the state of the IP3Rs (e.g. redox state, phosphorylation state, 
associated proteins, existence of heterotetramers) could explain this variability [1]. 
Taken together, most of the available evidence points to IP3R2 as being the most 
sensitive IP3R isoform. This observation raises the intriguing potential that IP3R2 can be 
active in the presence of basal, resting IP3 levels. 
 
2.2. Regulation by cytosolic Ca2+ 
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It has long been recognized that IP3R activity can be biphasically regulated by cytosolic 
Ca2+, meaning that a relatively low [Ca2+] (usually less than 0.3 M) potentiate IP3-
induced Ca2+ release, while higher [Ca2+] lead to an inhibition of the IP3R. Plotting IP3R 
activity against [Ca2+] therefore leads to a typical bell-shaped curve. The original 
observations were obtained in smooth muscle [55], neurons [56, 57] and oocytes [58], 
all tissues later shown to be particularly rich in IP3R1. It was therefore a long standing 
question whether this property was uniquely related to this isoform or whether IP3R2 
and IP3R3 shared this property. 
Although the stimulatory effect of Ca2+ on IP3R2 (and IP3R3) activity has never been in 
doubt, the inhibitory action of a high [Ca2+] was not always clearly observed. The group 
of Mignery published single-channel data demonstrating that both IP3R2 endogenously 
expressed in heart [51] or recombinantly expressed IP3R2 [59] displayed a much 
broader bell-shaped dependence towards Ca2+, meaning that on the one hand the 
stimulatory phase starts at a much lower [Ca2+] than for IP3R1, and on the other hand 
that IP3R2 remains active at a [Ca
2+] already fully inhibiting IP3R1. In contrast to these 
reports, the group of Bezprozvanny found quite similar (and narrow) [Ca2+] response 
curves for each of the three IP3R isoforms heterologously expressed in Sf9 insect cells 
and investigated in planar lipid bilayers [60].  
As will be further explained below (see section 2.3), the sensitivity of the IP3R2 towards 
Ca2+ is not dependent on the presence of ATP, but the latter will increase the likelihood 
of IP3R2 being in an open state at all [Ca
2+] (Figure 2). 
Taken together, these results indicate that IP3R2, similarly to the other IP3R isoforms, is 
regulated in a biphasic way by the cytosolic [Ca2+], though that depending on the exact 
state of the receptor, different sensitivities to Ca2+ can be observed. 
 
2.3. Regulation by ATP 
2.3.1. Regulation of IP3R2 is distinct from other IP3Rs 
Adenine nucleotides were recognized by early studies [61-68] as important regulators of 
IP3-induced Ca
2+ release, raising the attractive possibility that channel activity could be 
fine-tuned to match the metabolic status of the cell. The diversity of cell types in which 
ATP modulates IP3-induced Ca
2+ release is consistent with a regulation affecting all 
IP3R family members. However, two initial studies reported that in contrast to IP3R1 and 
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IP3R3, IP3R2 was not subject to modulation by adenine nucleotides [48, 52]. 
Specifically, studying individual mammalian isoforms reconstituted in planar lipid 
bilayers, Bezprozvanny and colleagues reported that under conditions optimal for 
channel activity IP3R2 had no requirement for ATP [52]. This observation was 
independently confirmed studying Ca2+ release from DT40 cells expressing a single 
IP3R isoform following genetic ablation of the other family members [48]. These reports 
are, in hindsight, important because they provide the first indication that ATP regulation 
of IP3R2 was distinct from the other family members. A subsequent detailed analysis of 
individual mammalian isoforms expressed in the DT40 TKO IP3R null background 
confirmed these earlier reports [69]. IP3R2 was indeed, in contrast to other IP3R family 
members, insensitive to ATP at maximal [IP3]. Nevertheless, it was demonstrated that 
IP3R2 activity, measured as Ca
2+ release, or at the single channel level in “on-nucleus” 
patch clamp recordings, was markedly enhanced at sub-saturating [IP3] [69]. Moreover, 
the sensitivity of ATP regulation of IP3-induced Ca
2+ release also differed between 
individual isoforms under identical conditions with IP3R2 being strikingly more sensitive 
than IP3R1 or IP3R3 (EC50 40 M, 100 M and 500 M for IP3R2, IP3R1 and IP3R3 
respectively) [69, 70]. An issue posed by these data is the concentration range of ATP 
that might be expected to dynamically regulate IP3R activity. In turn, this raises the 
question whether modulation occurs at physiological levels of nucleotides or is only 
relevant under pathological conditions when ATP is depleted. Given the cellular levels 
of MgATP (~1 mM) and “free” ATP3- and ATP4- (10-100 M) the answer is 
fundamentally dependent on the “species” of ATP that regulates IP3R channel activity. 
Several studies have addressed this issue and have reached disparate conclusions [67, 
71-73] and thus this important issue as well as the consequences of the high functional 
affinity of IP3R2 remains to be resolved. 
2.3.2. Putative peptide motifs in IP3R2 responsible for ATP regulation 
Modulation of IP3R activity is widely believed to occur by ATP binding to glycine-rich 
domains (Gly-Xaa-Gly-Xaa-Xaa-Gly), reminiscent of Walker type A repeats, present in a 
number of proteins that utilize ATP in a catalytic manner [74-77]. Consistent with this 
idea, a number of studies using either photo-affinity or fluorescent ATP probes have 
demonstrated binding to regions of IP3R or glutathione S-transferase-recombinant 
fragments harbouring these putative recognition sites [69, 75-77]. The primary 
sequence of IP3R2 contains one such motif, Gly-Leu-Gly-Leu-Leu-Gly, spanning amino 
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acids 1969-1974, which has been termed the “ATPB” site (Figure 1). Mutagenesis of 
three Gly residues to Ala in the motif eliminated binding of ATP and nucleotide 
regulation of Ca2+ release, confirming the functional importance of the ATPB site in 
IP3R2 [69]. Moreover, in cells expressing IP3R2 with an ATP binding-deficient ATPB 
motif, the frequency and amplitude of B cell receptor-activated Ca2+ oscillations were 
markedly reduced compared with wild-type IP3R2, suggesting strongly that nucleotide 
regulation of Ca2+ release is at least, constitutively required to shape cytosolic Ca2+ 
signals at physiologically relevant ATP levels [69]. Unexpectedly, mutations of all known 
Walker A motifs in IP3R1 and IP3R3 failed to abrogate nucleotide modulation [70]. The 
somewhat surprising conclusion is therefore, that ATP regulation of IP3R1 and IP3R3 is 
independent of known ATP-binding motifs, and thus the identity of molecular sites of 
nucleotide regulation in these IP3R remains to be elucidated. Consequently, the ATPB 
site in IP3R2 is unique as the only molecular locus for regulation of IP3R family 
members by adenine nucleotides that is defined unequivocally. 
2.3.3. Mechanism of ATP regulation of IP3R2 
Several studies have investigated the biophysical basis for ATP regulation of IP3R 
channel activity. In accordance with the singular features of IP3R2 when compared with 
other family members, it also appears that ATP regulates IP3R2 in a similarly distinctive 
manner. Using “on-nucleus” patch clamp single channel recordings of both endogenous 
Xenopus IP3R1 or rat IP3R1 expressed in DT40 TKO cells, elevating ATP levels 
increased the channel open probability (Po) by modulating the sensitivity of the channel 
to both activating and inhibitory [Ca2+], essentially left-shifting the bell-shaped [Ca2+] 
versus Po relationship at a given [IP3] [78, 79].  
In contrast, while IP3R2 displays an identical biphasic Ca
2+ sensitivity when exposed to 
saturating [IP3] (conditions in which IP3R2 is insensitive to ATP), at low [IP3], the Ca
2+ 
sensitivity of mouse IP3R2 was not altered by increasing ATP [79]. Elevating ATP 
simply dramatically enhanced Po, resulting in a marked increase in activity. A detailed 
kinetic analysis of the channel gating also indicated that IP3R2 displayed “bursting” 
activity with properties distinct from IP3R1 (Figure 2). Specifically, with elevated ATP, 
the number of bursting episodes of relatively constant duration was increased, while 
IP3R1 bursts simply lengthened in time. By analogy to a gear change in a car, we have 
termed this the transition from ‘park’ into a ‘drive’ mode. A minimal scheme to describe 
the channel kinetics at sub-saturating [IP3] suggests that both channels transition 
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between single open and closed states during drive mode with relatively constant 
kinetics and then are “parked” in a longer-lived closed state in the interburst intervals 
[79]. In the case of the IP3R1, increasing Ca
2+ and ATP facilitates bursting by facilitating 
both the transition out of the parked state and also by decreasing the likelihood it will 
return to this state. In contrast, [Ca2+] does not influence the time the IP3R2 spends in 
drive mode but simply destabilizes the parked state to initiate activity (Figure 3). 
Increasing ATP then appears to markedly increase overall channel Po by prominently 
decreasing the amount of time in the parked state [79]. This unique property results in 
dissociation of the modulation of IP3R2 activity by ATP from the [Ca
2+] in its immediate 
environment and likely allows added flexibility for tuning Ca2+ signals to the needs of the 
cell. 
2.3.4. Dominance of IP3R2 ATP regulatory characteristics 
An important question exists as to how the distinct features of individual IP3R subtypes 
are reflected in the overall characteristics of Ca2+ release from heterotetrameric 
channels. Specifically, are the properties simply a blended integration of the individual 
subtypes or can a particular subtype dominate the overall characteristics? Studies 
investigating ATP regulation of Ca2+ release in cells expressing multiple IP3R isoforms 
indicate that the latter possibility occurs, specifically when IP3R2 is expressed. For 
example, the characteristics of ATP regulation of IP3R2 (albeit the lack of regulation at 
saturating [IP3]) were observed in DT40 cells engineered to express only IP3R2, or in 
cells expressing both IP3R2 and IP3R1 or IP3R3 [48]. Similarly, in salivary and 
pancreatic acinar cells [80, 81], which natively express IP3R2 and IP3R3 to 
approximately equal extents, the features of ATP regulation precisely match those 
documented for IP3R2 stably expressed in isolation in either DT40 TKO [69] or in AR42J 
pancreatoma [80] cells (i.e. absence of regulation at saturating [IP3] and EC50 for ATP 
~40 M). Notably, similar experiments in pancreatic and parotid acinar cells prepared 
from IP3R2 null animals revealed identical properties to IP3R3 (i.e. regulation at all [IP3] 
and EC50 for ATP ~500 M) [80, 81]. Conversely, “rescue” experiments ectopically 
expressing IP3R2 in RINm5F insulinoma cells which predominately express IP3R3, 
converted IP3R3 characteristics to IP3R2 [80]. While these data clearly indicate the 
dominant influence of IP3R2 expression and are consistent with this occurring as a 
function of heterotetramer formation, these data could also formally be explained by an 
intermolecular interaction between clusters of homotetrameric IP3R. This issue has 
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recently been tackled by generating tetrameric IP3R from concatenated IP3R dimers 
connected by short flexible linkers [82]. Expression of dimers results in the assembly of 
tetramers where the subunit composition can be unequivocally defined. Expression of 
dimers of IP3R1 or IP3R2 exhibited the distinctive properties of ATP regulation typical of 
channels assembled from their respective monomeric parent subtype. Remarkably 
when heterodimers of IP3R1 and IP3R2 were expressed, resulting in assembly of 
channels consisting of equal numbers of IP3R1 and IP3R2 subunits, ATP regulation was 
indistinguishable from IP3R2, thus recapitulating the dominant effects seen in cells 
expressing native receptors [82]. These data indicate that IP3R2 in the context of a 
heterotetrameric channel exerts a dominant influence. Further work is needed to 
establish the number of monomers of IP3R2 necessary to exert this influence and 
whether IP3R2 similarly is the principle monomer that dictates the overall channel 
properties when subjected to other forms of regulation. 
 
2.4. Regulation by phosphorylation 
Like for many other ion channels, phosphorylation/dephosphorylation reactions provide 
a versatile, reversible form of acute regulation of IP3R activity. IP3Rs have been shown 
to be biochemical substrates for numerous families of serine/threonine and tyrosine 
directed kinases. In a more limited number of cases, a comprehensive documentation of 
the phosphorylation event, including location of the substrate motif and the subsequent 
functional consequences have been detailed. These studies have largely focused on 
IP3R1 as a template. With some notable exceptions, for example the AKT/PKB site 
conserved in the C-termini of each IP3R [83, 84], the amino acid motifs subject to 
phosphorylation events are not generally preserved between IP3R subtypes (Figure 1). 
Therefore, this form of regulation has the capacity to provide modulation of activity in an 
IP3R sub-type specific manner. Below we highlight reports that have specifically focused 
on regulation of IP3R2 activity. The interested reader is directed to Vanderheyden et al. 
[23] and Betzenhauser and Yule [85] for detailed discussion of IP3R phosphorylation 
and its functional consequences. 
2.4.1. Regulation of IP3R2 by protein kinase A (PKA) 
Historically, perhaps the most exhaustive investigation of IP3R modulation relates to 
PKA phosphorylation of IP3R1. Indeed, IP3R1 was identified as a major brain 
phosphorylated substrate even prior to the protein being appreciated as the receptor for 
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IP3 [86]. Subsequent studies demonstrated that IP3R1 is phosphorylated at serine 
residues within two canonical consensus motifs (Bas-Bas-Xaa-Ser/Thr, where Bas = a 
basic residue) [87, 88] and phosphorylation is associated with markedly enhanced Ca2+ 
release [89, 90]. To complete the strong case for IP3R1 being a functionally important 
PKA substrate, mutation of Ser1589 and Ser1755 to non-phosphorylatable alanine 
residues completely abrogates phosphate incorporation and the functional effects of 
PKA activation [90-92]. However, while PKA activation in cells that predominately 
express IP3R2 such as hepatocytes, parotid acinar cells and AR42J similarly results in 
enhanced Ca2+ release [93-95], the PKA substrate motifs present in IP3R1 are not 
conserved in IP3R2 [5]. In addition, while PKA activation results in IP3R2 
phosphorylation, phosphate incorporation is non-stoichiometric and indeed much 
reduced in comparison to IP3R1 [96]. Nevertheless, IP3R2 contains approximately 30 
serine or threonine residues, which constitute minimal PKA consensus motifs consisting 
of basic residues preceding the phosphorylated amino acid at the -2 and -3 positions 
(Bas-Bas-Xaa-Ser/Thr). Using an approach based on expressing consecutive domains 
of IP3R2 with N-terminal epitope tags, it was shown that PKA could only specifically 
phosphorylate in vitro a peptide fragment consisting of amino acids 920-1583 [97]. 
Mutation of Ser937 to alanine (Ser937Ala) abrogated all phosphorylation of the fragment, 
pinpointing this residue as the PKA target site (Figure 1). Subsequently, it was shown 
that an antibody raised against phospho-Ser937 recognized IP3R2 after forskolin 
treatment in cells expressing IP3R2 but not cells expressing a mutant full-length 
receptor harbouring a Ser937Ala mutation [97]. Notably, Ser937 was independently 
identified as a phosphorylated residue in a proteomic screen of hepatocytes [98]. 
Importantly, PK  activation markedly potentiated IP3-induced Ca
2+ release in DT40 
TKO cells expressing IP3R2 but not Ser
937Ala IP3R2 thus establishing this motif as likely 
solely responsible for the PKA-mediated phospho-regulation of IP3R2 [97]. The Ca
2+ 
signalling machinery is a rich source of substrates responsible for cross-talk between 
cAMP and Ca2+ signalling which ensure fine-tuning of the Ca2+ signal and appropriate 
activation of effectors [99]. PKA phosphorylation of IP3R2 likely is an important site of 
this interaction in cells such as astrocytes, cardiac myocytes, hepatocytes and acinar 
cells that prominently express this family member.  
2.4.2. Regulation of IP3R2 by Ca
2+/calmodulin-dependent protein kinase II (CaMKII) 
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CaMKII are a family of serine/threonine kinases assembled as either homo- or 
heteromultimers derived from the products of four closely related genes [100]. As a 
Ca2+/calmodulin-regulated enzyme, this kinase is an important primary effector of IP3R-
induced Ca2+ release and accordingly plays prominent roles in regulating various signal 
transduction pathways including the translocation of transcription factors and activity of 
ion channels [101, 102]. Notably, IP3Rs are substrates for the kinase, which provides a 
regulatory loop following Ca2+ release. Early work suggested that IP3R1 was a substrate 
for CaMKII in vitro and that the sites were distinct from those phosphorylated by PKA 
[103], however the functional consequences were poorly defined. Subsequently, studies 
based largely on pharmacology, concluded that Ca2+ release from Xenopus oocytes 
and HeLa cells was attenuated following CaMKII activation [104, 105]. More recently, a 
thorough characterization of the molecular sites and functional consequences of the 
CaMKII-mediated phopho-regulation of IP3R2 has been reported. Using a similar 
approach to that used to identify PKA sites, the ability of CaMKII to phosphorylate IP3R2 
fragments in vitro was assessed. It was initially demonstrated that a candidate residue 
was present within a fragment encompassing the initial 1078 amino acids [106] and 
further refinement narrowed the potential phosphor-acceptor residue to within residues 
134-338 [107]. Subsequent mutagenesis of potential serines/threonine residues in 
CaMKII consensus motifs (Ser/Thr-Xaa-Asp) within this region [107] identified Ser150 as 
phosphorylated by CaMKII (Figure 1). This site is conserved in mammalian IP3R family 
members and ryanodine receptor (RyR) 2, suggesting a common mode of regulation in 
these channels. When incorporated in bilayers, CaMKII phosphorylation reduced the Po 
of IP3R2 and this effect was reversed by the CaMKII inhibitor KN62. Importantly, the 
reduced channel activity was absent in Ser150Ala IP3R2, indicating that the site was 
functionally relevant [107]. Notably, CaMKII colocalizes and interacts with IP3R2 in the 
nuclear envelope of cardiac myocytes [106, 108]. This interaction has been proposed to 
be functional important for cardiac remodelling during hypertrophy [109] (see section 4).  
2.4.3. Regulation of IP3R2 by protein kinase C (PKC) 
Cerebellar IP3R was also initially identified as a substrate for PKC with phosphorylation 
sites independent of those sites modified by PKA [103]. Interestingly, however, it was 
demonstrated that phosphorylation by PKC was enhanced by prior PKA 
phosphorylation indicating a potential additional layer of cross-talk between these 
prominent cellular signalling systems [110]. Similarly to CaMKII, because at least 
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conventional PKC family members are regulated by an elevation in Ca2+, PKC 
phosphorylation provides a potential feedback loop to regulate IP3R activity. To date 
however, the functional effects of PKC phosphorylation and the sites of phosphorylation 
are relatively poorly defined. Unfortunately despite the general appreciation of the 
amino acid motifs that constitutes a PKC consensus sequence and the presence of 
multiple such templates in IP3R, none have been experimentally defined. Furthermore, 
while PKC activation results in enhanced Ca2+ release from liver nuclei, presumably 
reflecting IP3R1 and IP3R2 activity [111], Ca
2+ release is inhibited in AR42J cells, which 
predominately express IP3R2 [112]. These disparate findings may reflect subtype-
specific regulation of IP3R given that the PKC consensus motif numbers and location 
are different in each family member [9]. However an additional consideration is that 
numerous proteins in the signalling pathway from plasma membrane receptor 
occupation to the generation of Ca2+ signals are substrates for PKC and thus caution 
must be taken in interpreting data generated from indirect measurements of IP3R 
activity. Our own experience is that IP3R2 single channel activity recorded in either 
DT40 cell nuclei or in DT40 plasma membranes was unaffected by phorbol ester 
treatment or recombinant PKC exposure (Wagner, Chandrasekhar and Yule; 
unpublished observations). These data might indicate that IP3R is not a direct substrate 
for PKC. Yet, we cannot formally exclude the possibility that a scaffolding or anchoring 
protein necessary for activity is absent from the DT40 system. Hence, further work is 
required to characterize the impact of PKC on IP3R activity in general and on IP3R2 in 
particular.  
 
2.5. Other characteristics of IP3R2 
All the characteristics discussed above (see sections 2.1-2.4) have been the subject of 
extensive investigations. There are however, a few less studied properties, which 
nevertheless might be very interesting for understanding the cellular function of IP3R2. 
2.5.1. Regulation of IP3R2 by cAMP 
Similarly to the other IP3R isoforms, many accessory proteins interact with, and 
modulate IP3R2 function. These proteins include regulatory and structural proteins, 
many of which were also reported to interact with IP3R1 and/or IP3R3 [1, 2, 14].  
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An interesting exception is the interaction described between IP3R2 and type 6 
adenylate cyclase (AC6) [113]. In HEK 293 cells stably transfected with the type I 
parathyroid hormone receptor, a complex is formed between IP3R2, AC6 and Gαs [113, 
114]. This close association facilitates an exquisite regulation of IP3R2 by cAMP, and in 
addition, Ca2+ released through IP3R2 may control AC6 in a negative feedback loop. 
Importantly, the regulation by cAMP does not require the canonical ATP-binding site or 
the activity of PKA. Moreover, although all IP3R isoforms are potentially sensitive to 
cAMP, only IP3R2 has been unequivocally linked to a cAMP-producing enzyme (AC6) 
[114]. This mechanism can be of great general importance, since it provides a novel 
example of cross-talk between the cAMP- and the Ca2+-dependent pathways. 
2.5.2. Clustering and mobility of IP3R2 
All IP3R isoforms, including IP3R2 [115] are known to cluster in an agonist-dependent 
way [116] but a punctate distribution of IP3R2 has also been observed for native IP3R2 
[117] and heterologously expressed IP3R2 [41] in resting cells. This property can be 
correlated to the higher affinity of IP3R2 for IP3 (see section 2.1), which may allow the 
clustering to occur at basal, resting [IP3]. Interestingly, also other differences in 
behaviour were found between the different IP3R isoforms. A recent study performed in 
COS-7 cells confirmed that heterologously expressed IP3R2 showed a punctate 
distribution, in contrast to IP3R1 and IP3R3 that were uniformly distributed [118]. 
Moreover, IP3R2 appeared much less mobile than either the other IP3R isoforms or than 
other proteins involved in intracellular Ca2+ handling, such as RyR1 or 
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) 1. In addition, its mobility 
depended on its intracellular localization with the IP3R2 located in the perinuclear region 
having the lowest mobility. As the IP3R2 has the highest sensitivity to IP3 (see section 
2.1), its lesser mobility may determine the initiation sites for intracellular Ca2+ signals.  
 
3. The function of IP3R2 in secretory cells 
IP3R2 exhibits prominent expression in classical secretory cells (Table 1), including 
exocrine cells of the pancreas [119-121], salivary glands [81, 120-123], lacrimal gland 
[124], olfactory glands [125], liver [29], eccrine sweat glands [126] and the secretory 
epithelia of the biliary tree [127] and the intestine [18] and the goblet cells of the small 
intestine [128]. A common feature of these epithelial cells is that they are 
morphologically and functionally polarized to secrete fluid and protein across their apical 
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pole into a lumen forming a duct. Notably, the Ca2+ signal is centrally important to the 
primary secretory function of these cells by virtue of directly activating ion channels and 
the exocytotic machinery necessary for vectoral fluid and protein secretion [129, 130]. In 
exocrine glands, IP3R2 and IP3R3 are expressed in approximately equal numbers [12] 
and both family members are co-localized to a region immediately below the apical 
plasma membrane [119, 120]. This region has been termed “the trigger zone” because 
Ca2+ signals are invariably initiated in this region prior to the signal spreading as a Ca2+ 
wave towards the basal aspects of the cell [131-133]. There appears to be substantial 
functional redundancy between IP3R2 and IP3R3 in exocrine cells as mice null for either 
IP3R in isolation have no obvious phenotype. However, compound knockouts of IP3R2 
and IP3R3 have severe exocrine deficiency manifested as dry mouth [121], dry eye 
[124], pancreatic insufficiency [121] and attenuated mucus secretion [125]. As such, 
double knockouts are born normally but demise soon after weaning [121]. Indeed a 
detailed analysis of these mice have shown that Ca2+ signals in pancreatic, salivary, 
lacrimal and mucus glands are essentially unaltered in IP3R3 null mice [121, 124, 125] 
and only reduced to a modest degree at low [IP3] in IP3R2 null mice [80, 81, 121, 124, 
125]. These data suggest that IP3R2 is not generally essential for overall exocrine 
function. 
A possible exception to this idea has been highlighted by a recent study, which 
investigated the cause of a severe congenital sweating defect in a Pakistani family 
[126]. Ca2+ signalling is known to be important for sweat secretion and both IP3R2 and 
IP3R3 are expressed in the secretory cells of the sweat gland. A screen based on 
identifying regions of autozygosity in the genome of afflicted individuals revealed a 
mutation (Gly2498Ser) targeting an amino acid predicted to be critical to the function of 
the selectivity filter in the pore region of IP3R2. This mutation rendered the channel 
completely inactive when expressed in DT40 TKO cells, thus potentially explaining the 
defect observed in the patients. Consistent with this idea, subsequent studies showed 
that mice lacking IP3R2 exhibited a decreased ability to sweat although the effect was 
more modest than observed in humans. The differences in severity between the 
phenotype observed between mouse and human may reflect the relative levels of these 
subtypes in mouse versus human. Alternatively, the relatively mild phenotype in the 
mouse might be related solely to the knockout of IP3R2, reflecting some degree of 
compensation by the residual IP3R3. In this scenario the more severe effect in human 
could be due to the combined effect of ablation of IP3R2 pore function and a possible 
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dominant negative effect of the mutant IP3R2 when incorporated into heterotetramers 
containing IP3R3.  
The primary secretory function of hepatocytes is the secretion of bile and changes in 
intracellular Ca2+ play important regulatory roles in this process. Hepatocytes express 
predominantly IP3R2 (Table 1) with smaller amounts of IP3R1 and virtually no IP3R3. 
However, in contrast to exocrine acinar cells, each isoform exhibits a distinct sub-
cellular localization and therefore the isoforms appear not to have redundant functions. 
IP3R2 is enriched at the canalicular membrane, whereas IP3R1 has a more uniform 
distribution throughout structures in the cytosol [29]. Consistent with the sensitivity of 
IP3R2, agonist-induced Ca
2+ signalling is initiated through IP3R2 localized to the 
canalicular membrane [29, 134, 135] and Ca2+ release through this isoform is necessary 
for trafficking of the bile salt export pump to the canalicular membrane [134]. 
 
4. The function of IP3R2 in the heart 
As indicated (Table 1), cardiomyocytes are one of the cell types in which IP3R2 are 
highly expressed. Both atria and ventricles express IP3R2 [136] and consequently IP3R2 
channels have been implicated in both physiological and pathophysiological signalling in 
the heart.  
At the physiological level, Mikoshiba and co-workers showed that IP3R2 channels, 
together with IP3R1 channels, are critical for normal cardiogenesis [137]. Consistent 
with this, IP3R2 and IP3R1 are co-expressed in different parts of the embryonic heart, 
including atria, ventricle and atrioventricular canal, and in different cell types, including 
endothelial cells and cardiomyocytes, although timing differences in the appearance of 
IP3R2 versus IP3R1 exist. IP3R1/IP3R2 double knockout mice die in utero at embryonic 
stage E11.5 with major heart defects at the level of the ventricles (thin myocardial wall 
and poor trabeculation) and the atrioventricular canal (reduced number of cells). These 
defects were associated with a decrease in endocardial and myocardial cell 
proliferation. Furthermore, mesenchymal cells were lacking at the level of the 
developing atrioventricular canal. The authors hypothesized that this phenotype was 
due to the absence of IP3R-mediated Ca
2+ signalling, downstream of the activation of 
the Ca2+/calmodulin-dependent phosphatase calcineurin and of the translocation of 
NFATc to the nucleus. Indeed, in an ex vivo epithelial-mesenchymal transition (EMT) 
assay, the defect in EMT in atrioventricular explants derived from IP3R1/IP3R2 double 
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knockout mice could be restored by transducing constitutively active calcineurin. 
Moreover, the phenotype of these mice resembled well the phenotypes of mice 
knockouts for calcineurin B [138] or for NFATc3/NFATc4 [139]. Interestingly, the defect 
in endocardial cells could also be observed in developing zebrafish exposed to 
calcineurin inhibitors, such as FK506 or cyclosporine A. Hence, from this study, it is 
clear that IP3R1 or IP3R2 channels are needed for activating calcineurin/NFATc 
signalling and endocardial cell proliferation in vertebrates. It is important to note that the 
presence of either IP3R1 or IP3R2 is sufficient to drive normal cardiac development, 
indicating redundant functions for these channels in this process. In addition to the 
cardiac crescent, or first heart field, giving rise to a linear beating tube, there is a second 
source of myocardial cells, which is termed the second heart field. However, with 
respect to the latter, it appears that there is a redundant role for IP3R1 and IP3R3 [140]. 
IP3R1/IP3R3 double knockout mice are characterized by hypoplasia of the outflow tract 
and the primitive right ventricle at E8.5-9.5, probably due to a defective Mef2c-Smyd1 
transcriptional pathway. 
At the functional level, IP3Rs were first shown to impact contractility and arrhythmias. 
Atrial myocytes express much higher levels of IP3R2 than ventricular myocytes [136]. 
They are activated in response to elevated extracellular agonist concentrations, e.g. 
after ischaemia or during disease. Endothelin-1-induced IP3R activation promotes the 
inotropy and the occurrence of arrhythmic events in atrial myocytes [141, 142]. While in 
basal conditions, the cardiac function of IP3R2 knockout mice was similar to one of wild-
type mice, the positive inotropic effect and the arrhythmic events induced by endothelin-
1 were absent in IP3R2 knockout mice [143]. Hence, the presence of IP3R2 appears to 
be not essential for the normal functioning of the rodent heart, which is in line with the 
normal phenotype of the IP3R2 knockout mice generated by Chen and co-workers [143] 
and by Mikoshiba and co-workers [121]. 
In the ventricle, far fewer IP3Rs are present but may still contribute to Ca
2+ regulation 
under baseline conditions [144-147]. Moreover, a study by Roderick and co-workers 
revealed that increased IP3R2-mediated Ca
2+ signalling, in response to enhanced IP3 
signalling, is responsible for inducing hypertrophic pathways after prolonged endothelin-
1 exposure of neonatal or adult rat ventricular cardiomyocytes [148]. Endothelin-1 
triggered the expression of atrial natriuretic factor (ANF), a marker for hypertrophy. 
Endothelin-1-induced hypertrophy was independent of excitation-contraction coupling, 
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but required IP3 signalling and downstream IP3R-mediated Ca
2+ release. The latter 
occurred in the perinuclear region, but not in the cytosol, while Ca2+ transients linked to 
excitation-contraction coupling occurred throughout the cardiomyocyte. Specifically 
buffering nuclear Ca2+ by nuclear-targeted calbindin prevented endothelin-1-induced 
ANF expression. The nuclear Ca2+ signal was mediated by IP3R2 channels, which were 
enriched in the perinuclear region and led to the activation of calcineurin and 
downstream NFATc1, which accumulated in the nucleus. 
The IP3R/calcineurin/NFATc1 hyperactivity also seems to be operative in response to 
prolonged -adrenergic signalling, which occurs during workload-induced cardiac 
hypertrophy via enhanced excitation-contraction coupling. Interestingly, this model led 
to increased endothelin-1 signalling. This involved the release of endothelin-1 and 
autocrine/paracrine-mediated hyperactivation of its receptor (ETAR), thereby triggering 
downstream IP3 signalling and Ca
2+-dependent calcineurin activation. In hypertrophic 
cardiomyocytes (e.g. derived from spontaneous hypertrophic rats or from aortic-banded 
mice), IP3R2 not only played a role in the nucleus, where its hyperactivation via 
increased IP3 signalling downstream of ETAR led to calcineurin/NFATc1 activation and 
ANF expression, but also became upregulated in the junctional sarcoplasmic reticulum 
[146]. Here, localization of IP3R2 coincides with RyR2 channels, thereby augmenting 
Ca2+ transients associated with excitation-contraction coupling or endothelin-1 
exposure. As a consequence, the IP3R2-mediated Ca
2+ rise during diastole may 
activate or sensitize RyR2 channels, resulting in spontaneous extra-systolic Ca2+-
release events and the occurrence of arrhythmias [147]. This increased “extra-nuclear” 
expression of IP3R2 was also found in human heart samples derived from patients with 
heart failure after ischemic dilated cardiomyopathy [146]. 
The upregulation of IP3R2 channels during cardiac hypertrophy was mediated via a 
dynamic and Ca2+-dependent regulation of miRNA-133a [149]. In normal physiological 
conditions, miRNA-133a expression is highly expressed in cardiomyocytes, thereby 
targeting the 3’ untranslated region of the IP3R2 mRNA. As a consequence miRNA-
133a reduces the basal expression of IP3R2 and thereby avoids hypertrophy or 
arrhythmias resulting from excessive Ca2+ signalling. Interestingly, limiting the 
expression of miRNA-133a using an antagomir led to hypertrophic signalling (evident 
from the increased ANF expression), which was dependent on IP3-induced Ca
2+ 
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release, since degrading IP3 using IP3 5-phosphatase limited the increase of ANF by 
miR-133a antagomir.  
The role of miR-133a in controlling IP3R2 expression and the initiation of hypertrophic 
markers was found both ex vivo and in vivo. In isolated, hypertrophic cardiomyocytes 
from spontaneous hypertensive rats, IP3R2 levels were elevated, while miRNA-133a 
was downregulated [149]. Overexpression of miRNA-133a in these hypertrophic 
cardiomyocytes reduced ANF expression to levels similar as control cardiomyocytes. In 
addition, in vivo application of miRNA-133a antagomir caused IP3R2 upregulation and 
hypertrophic signalling. Interestingly, increased IP3-induced Ca
2+ release was also 
involved in the decreased miRNA-133a expression in hypertrophic models. Indeed, 
lowering IP3 signalling by IP3 5-phosphatase transduction blunted the endothelin-1-
induced decrease in miRNA-133a and the concomitant increase in IP3R2 protein levels. 
Collectively, these findings indicate that during pathophysiological conditions associated 
with increased endothelin-1, increased IP3 signalling can lead to downregulation of 
miRNA-133a. The latter will lead to upregulation of IP3R2 protein levels, thereby further 
driving the downregulation of miRNA-133a by boosting IP3-induced IP3R2-mediated 
Ca2+ signalling. This perpetual feedback cycle will establish a new signalling network 
that favours the expression of hypertrophic genes like ANF (via hyperactivation of 
calcineurin/NFATc1) and the occurrence of arrhythmic events. 
The mechanism by which IP3-induced Ca
2+ release controls miRNA-133a expression 
seems to involve transcription factors like the serum response factor (SRF), which is 
negatively regulated by the homeodomain-only protein. SRF induces miRNA-133a 
expression and subsequent IP3R2 downregulation. However, during hypertrophy, IP3-
induced Ca2+ release may increase homeodomain-only protein expression, thereby 
recruiting class I histone deacetylase (HDAC) and limiting transcriptional activity of SRF. 
The importance of IP3 signalling and IP3R2 has also been elegantly addressed by 
Molkentin and co-workers by the generation of transgenic mice overexpressing an IP3 
sponge, which represents a mutated, high-affinity form of the IP3-binding core (to blunt 
endogenous IP3-induced Ca
2+ release by trapping IP3), or overexpressing IP3R2 (to 
boost IP3-induced Ca
2+ release) in cardiomyocytes [150]. Mice overexpressing the IP3 
sponge displayed reduced cardiac hypertrophy in response to chronic -adrenergic 
stimulation and angiotensin II stimulation. In contrast, IP3R2-overexpressing mice 
displayed only a mild cardiac hypertrophic phenotype under basal conditions. However, 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
23 
 
when cardiac hypertrophy was induced (e.g. using transverse aortic constriction, 
chronic -adrenergic stimulation or overexpression of Gq, an upstream phospholipase 
C activator) mice expressing high IP3R2 levels demonstrated increased hypertrophic 
responses. Under these conditions, mice expressing low levels of IP3R2 (except for 
transverse aortic constriction) also displayed enhanced cardiac hypertrophy. Moreover, 
IP3R2 channels, which already display high sensitivity to IP3, may be further sensitized 
by increased PKA signalling downstream of -adrenergic receptor stimulation leading to 
hyperphosphorylation of IP3R2 at Ser
937 [97] (see section 2.4.1). The increased 
sensitivity of IP3R2-expressing mice to cardiac hypertrophy-inducing conditions could be 
linked to increased calcineurin and NFAT signalling. Consistent with this, the 
augmented cardiac hypertrophic response in IP3R2-overexpressing mice were 
completely blunted when these mice were crossed with calcineurin B-knockout mice, 
indicating an essential role of calcineurin/NFAT signalling in response to hyperactive 
IP3R2-mediated Ca
2+ signalling. While from the above studies, calcineurin emerged as 
the downstream target of increased IP3R-mediated Ca
2+ signalling, it is important to 
note that also nuclear CaMKII has been implicated in altered transcription in response 
to cardiac hypertrophic endothelin-1 signalling [109]. Increased IP3 signalling in 
response to endothelin-1 triggers a unique nuclear Ca2+ signalling that does not occur 
during excitation-contraction coupling but activates CaMKII, which together with protein 
kinase D results in the phosphorylation and nuclear export of class II HDAC5, a 
transcriptional repressor. In healthy conditions, nuclear HDAC5 forms a complex with 
the transcription factor MEF2, thereby preventing the transcription of hypertrophic 
genes. In hypertrophic conditions, HDAC5 is exported from the nucleus, leading to de-
repression of MEF2 and the induction of hypertrophic genes. Interestingly, blocking 
IP3Rs using chemicals like 2-aminoethoxydiphenyl borate or using IP3R2-knockout 
mice, prevents the nuclear export of HDAC5 and subsequent activation of the 
hypertrophic transcription program.  
All these studies are consistent with a critical role for Ca2+ signalling via IP3R2 in cardiac 
hypertrophy, being in the nucleus and required for driving transcription of hypertrophic 
genes and in the junctional sarcoplasmic reticulum being responsible for driving extra-
systolic Ca2+ rises and contractions. Moreover, these studies all support the concept of 
distinct Ca2+ signalling compartments in cardiomyocytes, either in the cytosol during 
physiological excitation-contraction coupling driven by RyR2 channels or in the nucleus 
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during pathophysiological hypertrophic signalling driven by IP3 and IP3R2 channels 
[151]. 
 
5. The role of IP3R2 in cell death and in senescence 
Over the last 20 years, IP3R channels have emerged as key regulators that control cell 
death and survival in a variety of cellular systems [14, 152-154]. T cells deficient in 
IP3R1 are resistant to a variety of apoptotic triggers, including chemical stimuli, like 
corticoids, and biological stimuli, including excessive T-cell receptor stimulation and 
exposure to Fas ligand [155]. Interestingly, susceptibility to T-cell receptor stimulation 
could be restored by artificially rising the cytosolic [Ca2+] using the SERCA inhibitor, 
thapsigargin. Also, a role for IP3R3 has emerged in pro-apoptotic Ca
2+ signalling [156], 
because some studies proposed that this channel may be preferentially located in the 
mitochondrial ER-associated membranes. As such, IP3R3 channels are thought to be 
part of the “quasi-synaptic” Ca2+-transport complex between the ER Ca2+ stores and the 
mitochondria that can involve IP3Rs, GRP75 and VDAC1 [157, 158]. Nevertheless, it is 
becoming increasingly clear that all IP3R isoforms participate in apoptotic Ca
2+ 
signalling and/or influence the susceptibility of cells towards apoptotic stimuli. This can 
mean two things: i) not only IP3R3, but also IP3R1 and IP3R2 channels can be part of 
the ER-mitochondrial junction complexes, and ii) not only direct Ca2+ transfer into the 
mitochondria, but also other downstream Ca2+-dependent signalling pathways 
participate in triggering mitochondrial outer membrane permeabilization, the point-of-no-
return in apoptosis. Furthermore, it is important to emphasize that a complex interaction 
exists between IP3Rs and proteins from the B-cell lymphoma (Bcl)-2 family involved in 
the control of apoptosis, whereby several interaction sites for such proteins have 
already been identified on the IP3R [159-162]. 
IP3R-mediated Ca
2+ release can lead to calcineurin activation, which dephosphorylates 
the pro-apoptotic “sensitizer” BH3-only protein, Bad [163, 164]. Phosphorylated Bad is 
neutralized due to its scaffolding with 14-3-3 proteins and therefore it cannot form a 
complex with anti-apoptotic Bcl-Xl [165]. Dephosphorylation of Bad by calcineurin, e.g. 
in response to increases in cytosolic [Ca2+] mediated by IP3Rs [164], results in Bad 
release from 14-3-3 proteins and its translocation from the cytosol to the mitochondrial 
membranes. Here, it can bind to and inhibit anti-apoptotic Bcl-Xl proteins [163], thereby 
displacing Bim/tBid, which then can activate Bax/Bak and induce apoptosis.  
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These data indicate that dampening the IP3R-mediated Ca
2+ rise, either by lowering 
IP3R levels or altering the IP3R-expression profile, by inhibiting the Ca
2+-flux properties 
of IP3Rs, or by lowering the ER Ca
2+ content, which decreases the driving force for Ca2+ 
release into the cytosol upon IP3R activation, will be cytoprotective [162]. Not 
surprisingly, different pro-survival signalling mechanisms, which are often oncogenic, 
appear to have exploited this concept to promote cell survival, including the survival of 
malignant or altered cells. In many cases, different mechanisms can be simultaneously 
operative. For instance, oncogenic KRAS mutations appear to switch the expression 
from IP3R3 into IP3R1 and to lower the ER Ca
2+-store content, together suppressing 
agonist-induced Ca2+ release and mitochondrial Ca2+ accumulation and thus protecting 
cells against menadione exposure [166]. AKT/PKB phosphorylates all three IP3R 
isoforms, thereby suppressing their pro-apoptotic Ca2+-release function [84, 156]. This 
mechanism is also exploited by tumour suppressors like the promyelocytic leukemia 
protein, which enhance IP3R3 activity by counteracting PKB-mediated IP3R3 
phosphorylation [167]. Other survival/anti-apoptotic proteins, like Bcl-2, have been 
reported to lower ER Ca2+ store-content by sensitizing IP3Rs to basal IP3 levels and to 
directly suppress IP3R-mediated Ca
2+ release, thereby preventing toxic mitochondrial 
Ca2+ overload [168]. Evidently, these mechanisms will also result in reduced calcineurin 
activation, thereby limiting Bad dephosphorylation and its subsequent inhibitory effects 
on the anti-apoptotic Bcl-2 proteins.  
While most studies have addressed the role of IP3R1 and IP3R3 channels in apoptosis, 
there is emerging evidence that IP3R2 channels play a crucial role in mediating pro-
apoptotic Ca2+ signalling. Definitely, IP3R2 with its high sensitivity to IP3 (see section 
2.1) may actually be a very critical regulator of cell survival versus cell demise by 
rendering cells sensitive to basal IP3 signalling. The role of IP3R2 in cell death has been 
elucidated in different studies and using different approaches. 
First of all, there is evidence that cell death triggered by cellular exposure to cytotoxic 
compounds or agents that induce oxidative stress has been associated with an increase 
in IP3R2 levels and activity. lncreasing oxidative stress in a neuronal cell line exposed to 
sub-lethal concentrations of tert-butyl hydroperoxide-mediated oxidative stress led to 
prominent upregulation of IP3R2 mRNA and protein levels, while IP3R1 and IP3R3-
expression levels remained unaltered [38]. Consistent with elevated IP3R expression 
levels, Ca2+ release from the nucleoplasm in response to a cell-permeable IP3 ester was 
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strongly potentiated in tert-butyl hydroperoxide-treated cells. Also, the nephrotoxic 
compound uranyl acetate has been shown to increase IP3R2 mRNA and protein levels 
in human epithelial kidney cells, thereby increasing the basal cytosolic [Ca2+] and 
apoptosis levels [169]. Similar findings have been reported in HeLa cells exposed to fast 
H2S donors, although in this case IP3R1 expression levels were also increased [170]. 
Interestingly, IP3Rs may also be directly affected by reactive oxygen species (ROS) 
[171]. In intact DT40 cells, superoxide anions caused Ca2+ release from the ER, likely 
via a mechanism that sensitizes IP3Rs to basal levels of IP3 signalling. In these DT40 
cells, the presence of IP3R2 and IP3R1 isoforms, but not of IP3R3, was required for 
superoxide anion-induced [Ca2+] rise in the cytosol. 
The role of IP3R2 channels in apoptotic Ca
2+ signalling was also identified in B-cell 
cancer cells, in particular in a subset of “primed to death” diffuse large B-cell lymphoma 
cell lines [172]. Cells expressing high IP3R2 levels seem “addicted” to the presence and 
recruitment of anti-apoptotic Bcl-2 proteins at the ER and especially in the IP3R protein 
complex [173]. By interacting via its BH4 domain with the modulatory and transducing 
domain of the IP3Rs, Bcl-2 inhibits IP3-induced Ca
2+ release [174-176]. The binding site 
for the BH4 domain of Bcl-2 (Figure 1) has been identified [175] and is conserved 
between the three IP3R isoforms [177]. Importantly, a peptide tool designed to disrupt 
IP3R/Bcl-2-complexes by targeting Bcl-2’s BH4 domain (see [175-178]) was very 
effective in inducing intracellular Ca2+ overload and provoking cell death in DL-BCL cells 
that express high levels of IP3R2, like SU-DHL-4 cells [172]. In contrast, cells that 
expressed very low levels of IP3R2 were virtually resistant to this peptide tool. The 
apoptotic resistance of these cells to this peptide was not due to a general defect in the 
initiation or execution of apoptosis, since staurosporine or BH3-mimetic drugs were very 
effective in these cells. We hypothesize that anti-apoptotic Bcl-2 is required at the ER to 
associate with the IP3R2 to prevent its hyperactivity in response to the ongoing IP3 
signalling downstream of the B-cell receptor [173]. It remains to be elucidated whether 
these findings translate into primary B-cell cancer cells. In any case, disrupting 
IP3R/Bcl-2 complexes results in excessive Ca
2+-signalling patterns and apoptotic cell 
death in primary peripheral mononuclear blood cells (mainly B cells) isolated from 
chronic lymphocytic leukaemia patients [179]. Remarkably, a gene expression profile 
analysis using the GeneSapiens microarray database revealed an upregulation of IP3R2 
at the mRNA level in chronic lymphocytic leukaemia samples [173].  
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IP3R2 channels are not only implicated in apoptosis but also play a role in cellular 
senescence. Stable cell cycle arrest is a key feature of cellular senescence, which is 
activated in response to cellular stress. Factors include oncogenic stress following loss 
of PTEN function, DNA damage or telomere attrition, oxidative stress and replicative 
stress [180]. The arrest in proliferation depends on the major tumour suppressor 
pathways involving p53/p21 and p16/Rb [180, 181]. At the physiological level, cellular 
senescence contributes to ageing at the level of the organism [182]. However, cellular 
senescence can also function as an important “health keeper” fighting 
pathophysiological conditions associated with oncogenic stress [183, 184]. As such, 
cellular senescence, in addition to apoptosis, is one of the pathways that counteract 
cancer cell initiation and tumour development [185, 186]. For instance, in pre-malignant 
hepatocytes, senescence led to the secretion of chemo- and cytokines, resulting in their 
clearance by CD4+ T cells [187]. Loss of immune surveillance caused the progression of 
the pre-malignant hepatocytes into hepatocellular carcinomas. Recently, Wiel et al. 
[188] performed an elegant shRNA-based screen to identify which “loss-of-function” 
genes can cause escape from oncogene-induced senescence in immortalized human 
mammary epithelial cells (HEC). Interestingly, the gene coding for IP3R2 was identified 
as a prominent modulator of this form of senescence. These findings correlated with an 
analysis performed by the authors using the Oncomine database, which indicated that 
many malignant tumours displayed a decrease in IP3R2 mRNA levels. IP3R2 shRNAs 
alleviated the growth arrest in HEC exposed to oncogenic stress. Prolonged incubation 
of these cells with cell-permeable IP3 repressed cell growth and induced pre-mature 
senescence. Oncogenic stress-induced senescence led to an increase in the Ca2+ 
accumulation in the mitochondria, a process that did not occur in the IP3R2 shRNA-
treated cells, and also boosted IP3-induced mitochondrial Ca
2+ uptake. This 
mitochondrial Ca2+ uptake was proposed to be responsible for the decrease in 
mitochondrial potential observed during oncogene-induced senescence, because 
shRNA against the IP3R2 or against the mitochondrial Ca
2+ uniporter prevented this 
decline in mitochondrial potential. Interestingly, chemical induction of mitochondrial 
depolarization blocked cell growth and induced pre-mature senescence. The role of 
IP3R2 and of the subsequent mitochondrial Ca
2+ accumulation was linked to an 
increase in ROS production, since anti-oxidants promoted oncogene-induced 
senescence escape. Finally, these concepts may not be limited to oncogene-induced 
senescence, but may also be applicable in models of replicative senescence. IP3R2 
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knockdown counteracted the increase in mitochondrial Ca2+ and the decline in 
mitochondrial potential observed during replicative senescence, thereby delaying the 
occurrence of senescence in these models. 
 
6. Conclusions 
IP3R2 is characterized by a number of important and specific properties, including, but 
not limited to, its high sensitivity to IP3 and ATP. Other properties such as its regulation 
by protein kinases, its interaction with adenylate cyclase to couple to cAMP production, 
its ability to recruit associated proteins and its low mobility in the ER, remain 
underexplored. At the functional level, it is clear that IP3R2 is not only important for 
regulating secretion, but also is implicated in health and disease, including prominent 
roles in cardiac function and tumour growth. The available evidence indicates that 
tumour cells either downregulate IP3R2 expression or dampen its activity via Bcl-2, 
since IP3R2 can promote senescence and/or apoptosis. It is now anticipated that further 
research will elucidate additional important functions of IP3R2 in other tissues and 
organs and further that developing tools specifically targeting or impacting IP3R2 will 
allow modulating its function in disease states. 
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Legends to the figures. 
 
Figure 1. Linear representation of the IP3R2 based on the human sequence 
demonstrating the interaction sites for its major regulators. The IP3R2 is 
represented in blue; the 5 functional domains are indicated. In the channel domain, the 
6 transmembrane helices as well as the connecting loops are depicted in green. The 
specific regulatory mechanisms discussed in the text are shown: identified 
phosphorylation sites are represented in dark blue, interaction sites for ATP and for Bcl-
2 are in orange and the recently described Gly2498Ser mutation in the pore domain 
affecting IP3R2 function [126] is depicted in red. 
 
Figure 2. Modulation of IP3R2 single-channel activity by IP3, Ca
2+ and ATP. 
Representative single channel recordings of IP3R2 expressed in DT40 TKO cells using 
the “on-nucleus” configuration of the patch-clamp technique. In A, channel activity was 
stimulated with a maximal [IP3] (10 µM) at the indicated [Ca
2+] and [ATP] (10 µM, in 
blue; 5 mM, in black). The pooled data in B reveal that channel activity stimulated by 
maximal [IP3] is modulated by [Ca
2+] in a biphasic manner and that this relationship is 
unaffected by increasing the [ATP]. In C, channel activity was stimulated with a sub-
maximal [IP3] (1 µM) at the indicated [Ca
2+] and [ATP] (10 µM, in blue; 5 mM, in black). 
The pooled data in D demonstrate that while channel activity is also biphasically 
regulated by [Ca2+] at sub-maximal [IP3], the maximally achievable open probability, at 
each [Ca2+], is, in contrast to what happens at a maximal [IP3], markedly potentiated in 
the presence of a high [ATP]. Modified from [79], with permission. 
 
Figure 3. “Park and Drive” model for IP3R1 and IP3R2 gating. An increase in IP3R1 
(A) and IP3R2 (B) channel activity in the presence of activating ligands is characterized 
by an increase in channel “bursting” without altering the intraburst kinetics. The bursts 
have subtype specific characteristics. A gating scheme for both channels can minimally 
be described by three states; one open state (in green) and two closed states (in red). 
Bursting activity is represented by rapid transitions between the open state (O) and a 
short-lived closed state (C1) representing the “Drive Mode” of the channel. In the 
interburst intervals, the channel is effectively “Parked” in a long-lived closed state (C2). 
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For both IP3R1 (A) and IP3R2 (B) increasing the concentrations of activating ligands 
solely alters the transition from C2 to C1. However, ligands both increase the likelihood 
that IP3R1 will leave the parked state to drive mode, as well as reciprocally decreasing 
the chances it will return to this state, thus extending the period of bursting (A). In the 
case of IP3R2, ligands only destabilize the parked state resulting in an increase in 
bursting episodes of relatively constant duration (B). 
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Table 1. Cell types or tissues predominantly expressing IP3R2. 
 
Cell type/tissues  Relevant references Specific remarks 
(in alphabetical order) 
 
AR42J   [11, 12]   Pancreatoma cell line 
Cardiac myocytes  [12, 13, 136, 189] 
Glia    [117, 190]  
Hepatocytes   [11-13, 29]   Polarized expression IP3R2 
Intercalated cells of  [191] 
renal collecting duct 
Pancreatic acinar cells [12]    IP3R3 ≈ IP3R2 
RBL-2H3   [11, 115, 192]  Mucosal mast cell line 
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Highlights: 
* The understanding of IP3R2 has long lagged behind that of the other IP3R isoforms 
* IP3R2 is an intracellular Ca
2+-release channel with important and unique properties 
* IP3R2 performs crucial physiological functions in various cell types 
* IP3R2 is implicated in health and disease, including cardiac hypertrophy and cancer 
* IP3R2 forms an important target for further research 
